TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20556834

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/d)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 74
Study: 18565433

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 4407

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4407
Study: 15925951

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE) with IF obesity
Number of subjects: 209

Group type: COMPARATOR
Intervention: Diet alone (DA) with IF obesity
Number of subjects: 209

Group type: COMPARATOR
Intervention: Diet alone (DA) with ASF obesity
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE) with ASF obesity
Number of subjects: 209
Study: 11818342

Group type: EXPERIMENTAL
Intervention: Information presented in terms of all risk reductions (absolute, relative, number needed to treat)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Information presented only in terms of relative risk reduction
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Information presented in terms of absolute risk reduction or number needed to treat
Number of subjects: 1500
Study: 10609696

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8578357

Group type: EXPERIMENTAL
Intervention: Eye patching (patched group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No eye patching (nonpatched group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (patched and nonpatched)
Number of subjects: 33
Study: 2007923

Group type: EXPERIMENTAL
Intervention: Formula with reduced protein content (1.3 gm/dl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard infant formula (protein 1.5 gm/dl)
Number of subjects: 20
Study: 6753887

Group type: EXPERIMENTAL
Intervention: Oral disopyramide phosphate (loading dose 150, 200, or 300 mg followed by 100, 150, or 200 mg every 6 hours based on weight)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oral disopyramide phosphate
Number of subjects: 121
Study: 30407649

Group type: EXPERIMENTAL
Intervention: KAATSU + PFMT
Number of subjects: 41

Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 41
Study: 27987229

Group type: EXPERIMENTAL
Intervention: Brain fatty acid-binding protein
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Plasma-free haemoglobin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Neuropsychological test scores
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Level of education
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Postoperative cognitive dysfunction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment
Number of subjects: 57
Study: 25858261

Group type: EXPERIMENTAL
Intervention: Doxycycline (oral, twice daily for 7 days)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 231
Study: 23321947

Group type: EXPERIMENTAL
Intervention: Heterosexual anal intercourse (HAI)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Casual partners
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Number of sex partners (for men)
Number of subjects: 980
Study: 21142946

Group type: EXPERIMENTAL
Intervention: Soymilk (500 mL daily for 21 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no soymilk)
Number of subjects: 42
Study: 19172254

Group type: EXPERIMENTAL
Intervention: Allicin (180 mg capsule once daily for 14 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16728906

Group type: EXPERIMENTAL
Intervention: 2 mg oral risperidone and 2 mg IM lorazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 mg oral haloperidol and 2 mg IM lorazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: oral placebo and 2 mg IM lorazepam
Number of subjects: 30
Study: 15584846

Group type: EXPERIMENTAL
Intervention: High contact with lineup administrator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low contact with lineup administrator
Number of subjects: 0
Study: 11334901

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Oral estrogens
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 17‐beta
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Progestogens
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: HRT (Hormone Replacement Therapy)
Number of subjects: 248
Study: 9284981

Group type: EXPERIMENTAL
Intervention: house-dust-mite allergen
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 8322566

Group type: EXPERIMENTAL
Intervention: 5 mg methadone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mg diamorphine
Number of subjects: 40
Study: 3540097

Group type: EXPERIMENTAL
Intervention: LeVeen shunt
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 57
Study: 31657234

Group type: EXPERIMENTAL
Intervention: MGDRx EyeBag®
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: OPTASETM Moist Heat Mask
Number of subjects: 42

Group type: COMPARATOR
Intervention: Warm face cloth
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All three groups (MGDRx EyeBag®, OPTASETM Moist Heat Mask, Warm face cloth)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 42
Study: 28140753

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 5.25 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (both dosages)
Number of subjects: 0
Study: 27473545

Group type: EXPERIMENTAL
Intervention: Potentized estrogen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26402703

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection of 50 U
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection of 100 U
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection of 200 U
Number of subjects: 30
Study: 22810954

Group type: EXPERIMENTAL
Intervention: Clinic-based recruitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet and social networking advertising
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone-based recruitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advertising on radio, television
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distributing brochures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word-of-mouth referrals
Number of subjects: 0
Study: 20542707

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied to bone grafts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cancellous bone and marrow grafts without PRP (Control group)
Number of subjects: 20
Study: 19928395

Group type: EXPERIMENTAL
Intervention: Dynamic FM system
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional FM system
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dynamic FM system with Autosensitivity
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional FM system with Autosensitivity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Use of Autosensitivity
Number of subjects: 25
Study: 17106700

Group type: EXPERIMENTAL
Intervention: rhTSH stimulation in group A (75 patients)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: rhTSH stimulation in group B (19 patients)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: rhTSH stimulation in group C (35 patients)
Number of subjects: 129
Study: 14970982

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tai Chi (alone or in combination with other therapies)
Number of subjects: 24
Study: 11694607

Group type: EXPERIMENTAL
Intervention: Full-strength tea (15 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeinated water (270 mg caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: COMPARATOR
Intervention: Half-strength tea (7.5 g)
Number of subjects: 12
Study: 9145339

Group type: EXPERIMENTAL
Intervention: Clinical practicum
Number of subjects: 0
Study: 10155730

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selective adsorption
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selective adsorption followed by i.v. IgG
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 2612235

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C)
Number of subjects: 120
Study: 856049

Group type: EXPERIMENTAL
Intervention: Betamethasone 0.1% as valerate in an ointment base
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fluocinonide 0.05% in a fatty alcohol propylene glycol (FAPG) base
Number of subjects: 76
Study: 31282395

Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises, posture and cervical region exercises for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise recommended, only posture information)
Number of subjects: 30
Study: 31199017

Group type: EXPERIMENTAL
Intervention: Two 2.5 hr sessions of psychoeducation and communication skills-based intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 44
Study: 27816035

Group type: EXPERIMENTAL
Intervention: Four sessions of smoking cessation counseling plus 12 weeks of bupropion treatment and brief physician advice to quit
Number of subjects: 500

Group type: COMPARATOR
Intervention: No counseling plus 12 weeks of bupropion treatment and brief physician advice to quit
Number of subjects: 500
Study: 25378648

Group type: EXPERIMENTAL
Intervention: Docetaxel 20 mg/m² plus cisplatin 25 mg/m² on Day 1, 8, and 15 (docetaxel plus cisplatin)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Docetaxel 25 mg/m² on the same schedule (docetaxel)
Number of subjects: 126
Study: 25604122

Group type: EXPERIMENTAL
Intervention: Neuropsychological measures assessing speed of information processing, memory, and executive functioning
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors (older age, lower education, first language other than English or French, Black or Other ethnicity, presence of psychosis)
Number of subjects: 1500
Study: 23572137

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: High-dose imatinib (800 mg) in combination with intermediate-dose cytarabine (200 mg/m2 for 7 days)
Number of subjects: 109
Study: 20800340

Group type: EXPERIMENTAL
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 204
Study: 18773733

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus in one interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus in both intervals
Number of subjects: 0
Study: 16616232

Group type: EXPERIMENTAL
Intervention: Lipo-ecraprost (60 microg, administered intravenously on each of 5 days per week for 8 weeks)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 12792559

Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11009123

Group type: EXPERIMENTAL
Intervention: Structured training protocol for BSE instruction
Number of subjects: 41
Study: 9212553

Group type: EXPERIMENTAL
Intervention: Nurse coach intervention
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nurse coach plus train parent and child intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard medical care condition
Number of subjects: 92
Study: 7962654

Group type: EXPERIMENTAL
Intervention: Conventional dose cyclosporin plus nifedipine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional dose cyclosporin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low dose cyclosporin plus azathioprine
Number of subjects: 3
Study: 3296733

Group type: EXPERIMENTAL
Intervention: 2 mg/kg i.v. bolus, then 20 mg/h by infusion for 4 h (low-dose continuous infusion metoclopramide)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 2 mg/kg i.v. bolus every 2 h for three doses (high-dose bolus metoclopramide)
Number of subjects: 16
Study: 29020355

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 or 25 mg once daily
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 27898732

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV acquisition
Number of subjects: 0
Study: 24423999

Group type: EXPERIMENTAL
Intervention: Cognitive forcing strategies (CFS) training
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 191
Study: 23870807

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 30
Study: 20594207

Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Community Control (CC)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Person-Centered Approach (PCA)
Number of subjects: 143
Study: 19064521

Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (2.5 mg folic acid/d, 50 mg vitamin B‐6/d, and 1 mg vitamin B‐12/d)
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2009
Study: 16880571

Group type: EXPERIMENTAL
Intervention: 1% metronidazole gel
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12657163

Group type: EXPERIMENTAL
Intervention: Tailored intervention including educational outreach visits, audit and feedback, and computerized reminders.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (passive dissemination of guidelines).
Number of subjects: 150
Study: 10840412

Group type: EXPERIMENTAL
Intervention: Complete androgen blockade
Number of subjects: 27
Study: 8645503

Group type: EXPERIMENTAL
Intervention: 150 mg eugenol for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 10
Study: 7515704

Group type: EXPERIMENTAL
Intervention: Kaolin-based activated coagulation time (AKT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-dose thrombin time (HITT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Celite-based activated coagulation time (ACT)
Number of subjects: 20
Study: 3606928

Group type: EXPERIMENTAL
Intervention: 6400 units ORG 10172
Number of subjects: 83

Group type: COMPARATOR
Intervention: 5000 units heparin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ORG 10172
Number of subjects: 83
Study: 31977509

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mechanochemical Ablation (MOCA)
Number of subjects: 150
Study: 31991063

Group type: EXPERIMENTAL
Intervention: Decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment
Number of subjects: 388

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 388
Study: 29331711

Group type: EXPERIMENTAL
Intervention: Omega-3 supplements (638mg DHA and 772mg EPA per day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Copra oil (placebo)
Number of subjects: 194
Study: 27474214

Group type: EXPERIMENTAL
Intervention: POWeR+Face-to-face (POWeR+F); up to seven nurse contacts over 6 months
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: POWeR+Remote (POWeR+R); up to five emails or brief phone calls over 6 months
Number of subjects: 818

Group type: COMPARATOR
Intervention: Control group; evidence-based dietetic advice with 6 monthly nurse follow-up
Number of subjects: 818
Study: 24717368

Group type: EXPERIMENTAL
Intervention: Reduction of 12 oz (355 mL)/d SSB (equivalent to 1 can of soda per day)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Reduction of 12 oz/d SSB (equivalent to 1 can of soda per day) after adjusting for confounders
Number of subjects: 144
Study: 23008102

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 282
Study: 20870863

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied to the motor and prefrontal cortices, 8 sessions over 2.5 weeks.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 25
Study: 18464224

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled corticosteroid and long acting‐b‐agonists (LABA) combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term combined therapy with inhaled corticosteroid and LABA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) in COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination inhalers (LABA and CS)
Number of subjects: 0
Study: 17059771

Group type: EXPERIMENTAL
Intervention: HES (6% hydroxyethyl starch)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GEL (4% succinylated gelatin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RL (lactated Ringer's solution)
Number of subjects: 60
Study: 14583311

Group type: EXPERIMENTAL
Intervention: milrinone
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (control)
Number of subjects: 30
Study: 11013194

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite implant
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acrylic implant
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy control eyes
Number of subjects: 34
Study: 8841214

Group type: EXPERIMENTAL
Intervention: Endocervical 0.5 mg of PGE2 gel
Number of subjects: 118

Group type: COMPARATOR
Intervention: Immediate oxytocin induction of labor
Number of subjects: 118
Study: 1517923

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) therapy (500 mg/kg)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Albumin treatment (5 mg/kg)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 753
Study: 6406435

Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupropion 450 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30700116

Group type: EXPERIMENTAL
Intervention: Short-TXA (three-hour two-dose regimen)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Long-TXA (11-hour four-dose regimen)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Comparison of short-TXA vs long-TXA
Number of subjects: 229
Study: 29975565

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (walking, 60%-70% of max HR) at -15°C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (walking, 60%-70% of max HR) at +22°C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Seated rest at +22°C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Seated rest at -15°C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise in the cold
Number of subjects: 16
Study: 26559450

Group type: EXPERIMENTAL
Intervention: 15RM Resistance Exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: 4RM Resistance Exercise
Number of subjects: 15
Study: 23602304

Group type: EXPERIMENTAL
Intervention: TimeSlips creative storytelling program (two one-hour sessions per week for six weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-of-care activity programming (control group)
Number of subjects: 20
Study: 22082250

Group type: EXPERIMENTAL
Intervention: Earplug-delivered sleep-inducing music for 52 min beginning at 10:00 pm, while wearing an eyeshield, n = 29
Number of subjects: 58

Group type: COMPARATOR
Intervention: No music, but earplugs and eyeshield worn, n = 29
Number of subjects: 58
Study: 20643703

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (8-week computerized program)
Number of subjects: 24
Study: 17463460

Group type: EXPERIMENTAL
Intervention: Drug intervention to prevent diabetes (specific drug not mentioned)
Number of subjects: 0
Study: 15045169

Group type: EXPERIMENTAL
Intervention: Low sedation level (Bloomsbury Sedation Score) and higher degree of consciousness (Glasgow Coma Scale)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Surgical ICUs
Number of subjects: 74

Group type: COMPARATOR
Intervention: Medical ICU/CCUs
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Risk assessment tool based on identified risk factors
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Systematic administration of the Bloomsbury Sedation Score and the Glasgow Coma Scale
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Reduction of sedative drugs during weaning, timely extubation, increased surveillance
Number of subjects: 74
Study: 12194393

Group type: EXPERIMENTAL
Intervention: 1 ml 0.5 mg neostigmine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 1 ml 2% lidocaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: 1 ml normal saline
Number of subjects: 105
Study: 9793813

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 micrograms, 37.5 micrograms, 50 micrograms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (5 micrograms, 10 micrograms, 15 micrograms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl and sufentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil
Number of subjects: 60
Study: 8602376

Group type: COMPARATOR
Intervention: zidovudine 600 mg/day alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: zidovudine with cimetidine 1200 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: zidovudine with ranitidine 300 mg/day
Number of subjects: 6